AMG-9810 References

AMG-9810
Identifiers
	IUPAC name (E)-3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide;
CAS Number	545395-94-6;
PubChem CID	680502;
ChemSpider	592741;
UNII	182HIJ2D7F;
ChEBI	CHEBI:92757;
ChEMBL	ChEMBL195789;
CompTox Dashboard ( EPA)	DTXSID40202960 ;
ECHA InfoCard	100.164.996
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.419 g·mol−1
3D model ( JSmol)	Interactive image;
	SMILES CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC3=C(C=C2)OCCO3;
	InChI InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)/b11-6+; Key:GZTFUVZVLYUPRG-IZZDOVSWSA-N;

AMG-9810 is a drug which acts as a potent and selective antagonist for the TRPV1 receptor.^[1] It has analgesic and antiinflammatory effects and is used in scientific research, but has not been developed for medical use. It has high antagonist potency and good bioavailability and pharmacokinetics, and so has been used to study the role of TRPV1 in areas other than pain perception, such as its roles in the brain.^[2]^[3]^[4]^[5]^[6]

References

^ Doherty EM, Fotsch C, Bo Y, Chakrabarti PP, Chen N, Gavva N, et al. (January 2005). "Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides". Journal of Medicinal Chemistry. 48 (1): 71–90. doi: 10.1021/jm049485i. PMID 15634002.
^ Okun A, DeFelice M, Eyde N, Ren J, Mercado R, King T, Porreca F (January 2011). "Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents". Molecular Pain. 7: 1744-8069–7-4. doi: 10.1186/1744-8069-7-4. PMC 3025866. PMID 21219650.
^ Shirazi M, Izadi M, Amin M, Rezvani ME, Roohbakhsh A, Shamsizadeh A (August 2014). "Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats". Neurological Sciences. 35 (8): 1235–41. doi: 10.1007/s10072-014-1689-5. PMID 24577898. S2CID 24122557.
^ Amiresmaili S, Shamsizadeh A, Allahtavakoli M, Pourshanazari AA, Roohbakhsh A (February 2014). "The effect of intra-ventral hippocampus administration of TRPV1 agonist and antagonist on spatial learning and memory in male rats". Pharmacological Reports. 66 (1): 10–4. doi: 10.1016/j.pharep.2013.06.002. PMID 24905300. S2CID 15631269.
^ Walters ET (August 2014). "Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense". Experimental Neurology. 258: 48–61. doi: 10.1016/j.expneurol.2014.02.001. PMID 25017887. S2CID 39671969.
^ Bannazadeh M, Fatehi F, Fatemi I, Roohbakhsh A, Allahtavakoli M, Nasiri M, et al. (May 2017). "The role of transient receptor potential vanilloid type 1 in unimodal and multimodal object recognition task in rats". Pharmacological Reports. 69 (3): 526–531. doi: 10.1016/j.pharep.2017.01.025. PMID 31994094. S2CID 210949267.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Doherty EM, Fotsch C, Bo Y, Chakrabarti PP, Chen N, Gavva N, et al. (January 2005). "Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides". Journal of Medicinal Chemistry. 48 (1): 71–90. doi: 10.1021/jm049485i. PMID 15634002.

[2] Okun A, DeFelice M, Eyde N, Ren J, Mercado R, King T, Porreca F (January 2011). "Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents". Molecular Pain. 7: 1744-8069–7-4. doi: 10.1186/1744-8069-7-4. PMC 3025866. PMID 21219650.

[3] Shirazi M, Izadi M, Amin M, Rezvani ME, Roohbakhsh A, Shamsizadeh A (August 2014). "Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats". Neurological Sciences. 35 (8): 1235–41. doi: 10.1007/s10072-014-1689-5. PMID 24577898. S2CID 24122557.

[4] Amiresmaili S, Shamsizadeh A, Allahtavakoli M, Pourshanazari AA, Roohbakhsh A (February 2014). "The effect of intra-ventral hippocampus administration of TRPV1 agonist and antagonist on spatial learning and memory in male rats". Pharmacological Reports. 66 (1): 10–4. doi: 10.1016/j.pharep.2013.06.002. PMID 24905300. S2CID 15631269.

[5] Walters ET (August 2014). "Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense". Experimental Neurology. 258: 48–61. doi: 10.1016/j.expneurol.2014.02.001. PMID 25017887. S2CID 39671969.

[6] Bannazadeh M, Fatehi F, Fatemi I, Roohbakhsh A, Allahtavakoli M, Nasiri M, et al. (May 2017). "The role of transient receptor potential vanilloid type 1 in unimodal and multimodal object recognition task in rats". Pharmacological Reports. 69 (3): 526–531. doi: 10.1016/j.pharep.2017.01.025. PMID 31994094. S2CID 210949267.

[1]

[2]

[3]

[4]

[5]

[6]

Identifiers

IUPAC name (E)-3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide
CAS Number	545395-94-6
PubChem CID	680502
ChemSpider	592741
UNII	182HIJ2D7F
ChEBI	CHEBI:92757
ChEMBL	ChEMBL195789
CompTox Dashboard ( EPA)	DTXSID40202960
ECHA InfoCard	100.164.996
Chemical and physical data
Formula	C₂₁H₂₃NO₃
Molar mass	337.419 g·mol⁻¹
3D model ( JSmol)	Interactive image
SMILES CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC3=C(C=C2)OCCO3
InChI InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)/b11-6+ Key:GZTFUVZVLYUPRG-IZZDOVSWSA-N

See also

References